Fairmount Funds Management LLC and related reporting persons amended a Schedule 13G to report beneficial ownership of 1,855,644 shares of Enliven Therapeutics, Inc. common stock, representing 3.1% based on 59,800,406 shares outstanding as of February 19, 2026 per the issuer's Form 10-K. The filing states that Fund II delegated sole voting and dispositive power to Fairmount and includes disclaimers of beneficial ownership under Section 13(d).
Positive
None.
Negative
None.
Insights
Large shareholder reports a 3.1% stake via Fund II with voting delegation.
The filing lists 1,855,644 shares and a 3.1% stake using an outstanding share base of February 19, 2026. It clarifies that Fund II delegated voting and dispositive authority to Fairmount.
Implications depend on whether the holder actively votes or trades; subsequent filings would disclose changes in position or voting intent.
Delegation and disclaimers limit Section 13(d) attribution despite reporting.
The statement explains Fund II delegated sole power to Fairmount and disclaims beneficial ownership for Section 13(d) due to a >61-day irrevocable delegation; Fairmount and its managers file to meet disclosure obligations.
Watch for future amendments or Form 13D/13G filings that would indicate changes in voting intent or ownership level.
Key Figures
Shares reported:1,855,644 sharesPercent of class:3.1%Outstanding shares (as of):59,800,406 shares
3 metrics
Shares reported1,855,644 sharesBeneficially owned by Fairmount/Fund II
Percent of class3.1%Based on 59,800,406 shares outstanding as of February 19, 2026
Outstanding shares (as of)59,800,406 sharesOutstanding as of February 19, 2026 per issuer's Form 10-K
Key Terms
Schedule 13G/A, beneficial ownership, shared dispositive power
3 terms
Schedule 13G/Aregulatory
"This Amendment No. 5 to amends and restates the statements"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficial ownershipfinancial
"The Common Stock reported herein includes Common Stock beneficially owned directly by Fund II"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
What stake does Fairmount report in ENLIVEN THERAPEUTICS (ELVN)?
Fairmount reports beneficial ownership of 1,855,644 shares, representing 3.1% of common stock. The percentage uses 59,800,406 shares outstanding as of February 19, 2026, per the issuer's Form 10-K.
Who holds the voting and dispositive power over these shares?
Fund II delegated sole voting and dispositive power to Fairmount Funds Management LLC. The filing states Fund II cannot revoke that delegation on less than 61 days' notice, which informs the reported disclaimers.
Do Fairmount's managers claim direct beneficial ownership?
The filing states that Peter Harwin and Tomas Kiselak file as managing members but disclaim beneficial ownership except for Section 13(d) reporting purposes. Their disclosures list shared voting and dispositive power over 1,855,644 shares.
When was this amendment signed and filed?
Signatures in the amendment are dated May 15, 2026. The document is labeled Amendment No. 5 and amends prior statements originally filed beginning April 27, 2023 through Amendment No. 4.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 5)
ENLIVEN THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
29337E102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
29337E102
1
Names of Reporting Persons
Fairmount Funds Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,855,644.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,855,644.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,855,644.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.1 %
12
Type of Reporting Person (See Instructions)
IA
Comment for Type of Reporting Person: The shares reported herein for the Reporting Person represent 1,855,644 shares of the Issuer's Common Stock held by Fairmount Healthcare Fund II LP ("Fund II").
The percentage calculation is based upon 59,800,406 shares of the Issuer's Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Form 10-K filed on March 3, 2026.
SCHEDULE 13G
CUSIP Number(s):
29337E102
1
Names of Reporting Persons
Fairmount Healthcare Fund II L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,855,644.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,855,644.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,855,644.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The shares reported herein for the Reporting Person represent 1,855,644 directly owned shares of the Issuer's Common Stock.
The percentage calculation is based upon 59,800,406 shares of the Issuer's Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Form 10-K filed on March 3, 2026.
SCHEDULE 13G
CUSIP Number(s):
29337E102
1
Names of Reporting Persons
Peter Harwin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,855,644.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,855,644.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,855,644.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The shares reported herein for the Reporting Person represent 1,855,644 shares of the Issuer's Common Stock held by Fund II.
The percentage calculation is based upon 59,800,406 shares of the Issuer's Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Form 10-K filed on March 3, 2026.
SCHEDULE 13G
CUSIP Number(s):
29337E102
1
Names of Reporting Persons
Kiselak Tomas
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SLOVAKIA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,855,644.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,855,644.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,855,644.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The shares reported herein for the Reporting Person represent 1,855,644 shares of the Issuer's Common Stock held by Fund II.
The percentage calculation is based upon 59,800,406 shares of the Issuer's Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Form 10-K filed on March 3, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ENLIVEN THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
6200 Lookout Road Boulder, CO 80301
Item 2.
(a)
Name of person filing:
This Amendment No. 5 to Schedule 13G amends and restates the statements on Schedule 13G originally filed on April 27, 2023, Amendment No. 1 filed on February 14, 2024, Amendment No. 2 filed on November 14, 2024, Amendment No. 3 filed on February 14, 2025, and Amendment No. 4 filed on August 14, 2025.
This joint statement on Schedule 13G (this "Statement") is being filed by Fairmount Funds Management LLC ("Fairmount"), Fairmount Healthcare Fund II L.P. ("Fund II"), Peter Harwin, and Tomas Kiselak. Fairmount, Fund II, Mr. Harwin, and Mr. Kiselak are collectively referred to herein as the "Reporting Persons."
The Common Stock reported herein includes Common Stock beneficially owned directly by Fund II. Fairmount Healthcare Fund II GP LLC is the general partner of Fund II. The controlling persons of Fairmount are Mr. Harwin and Mr. Kiselak. Fairmount serves as investment adviser for Fund II and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"), of any securities of the Issuer held by Fund II. Fund II has delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fund II's portfolio, including the shares of the Issuer's Common Stock reported herein. Because Fund II has divested voting and investment power over the reported securities and cannot revoke such delegation on less than 61 days' notice, Fund II disclaims beneficial ownership of the securities for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managing members of Fairmount, Mr. Harwin and Mr. Kiselak may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of the securities reported in this Statement other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that any of Fairmount, Mr. Harwin, or Mr. Kiselak is the beneficial owner of such securities for any other purpose.
(b)
Address or principal business office or, if none, residence:
c/o Fairmount Funds Management LLC, 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.
(c)
Citizenship:
Fairmount is a Delaware limited liability company. Fund II is a Delaware limited partnership. Mr. Harwin is a United States citizen. Mr. Kiselak is a Slovak Republic citizen.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
29337E102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See the response(s) to Item 9 on the attached cover page(s).
(b)
Percent of class:
See the response(s) to Item 11 on the attached cover page(s).
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See the response(s) to Item 5 on the attached cover page(s).
(ii) Shared power to vote or to direct the vote:
See the response(s) to Item 6 on the attached cover page(s).
(iii) Sole power to dispose or to direct the disposition of:
See the response(s) to Item 7 on the attached cover page(s).
(iv) Shared power to dispose or to direct the disposition of:
See the response(s) to Item 8 on the attached cover page(s).
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Fairmount Funds Management LLC
Signature:
/s/ Peter Harwin
Name/Title:
Peter Harwin, Managing Member
Date:
05/15/2026
Signature:
/s/ Tomas Kiselak
Name/Title:
Tomas Kiselak, Managing Member
Date:
05/15/2026
Fairmount Healthcare Fund II L.P.
Signature:
/s/ Peter Harwin
Name/Title:
Peter Harwin, Managing Member
Date:
05/15/2026
Signature:
/s/ Tomas Kiselak
Name/Title:
Tomas Kiselak, Managing Member
Date:
05/15/2026
Peter Harwin
Signature:
/s/ Peter Harwin
Name/Title:
Peter Harwin
Date:
05/15/2026
Kiselak Tomas
Signature:
/s/ Kiselak Tomas
Name/Title:
Kiselak Tomas
Date:
05/15/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on August 14, 2025)
